Mutation screening by qBiomarker array and validation with AmpliSeq next-generation sequencing platform in patient-derived tumour xenografts (PDX).(A) Tumour site distribution of 117 PDX models selected for mutation screening. (B) Number of somatic mutations (non-synonymous and indels) covered by the customised qBiomarker array. (C) Number of mutations identified per gene using the qBiomarker array (cyan bars). Mutation rates comparison for the most frequently mutated genes detected by qBiomarker (green inserts) in colorectal cancers, pancreatic carcinomas, non-small cell lung cancers and melanoma with mutation frequencies reported for these genes (including all reported mutations, not only the ones we analysed) in primary tumours by COSMIC (red inserts). (D) List of genes and number of somatic mutations concurrently covered by qBiomarker and AmpliSeq mutation detection platforms. (E) Schematic representation of all mutations detected by qBiomarker and AmpliSeq approaches in 59 PDX models. Green and blue dots represent mutations detected by either qBiomarker or AmpliSeq assay, respectively, whereas red dots indicate mutations concurrently detected by both methods. Cases with no mutation detected are not shown. (F) Venn diagram summarises mutations concurrently detected by both methods and each one of the tested techniques alone.